Keyword: Jazz Pharmaceuticals
Allergan CEO Brent Saunders' pricing pledge has left a distinct mark on the industry, officially or not, Bernstein data show.
Jazz won an FDA nod Thursday for its Vyxeo combination-chemo treatment, part of the company's bid to diversify ahead of Xyrem generics.
Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat over drug pricing practices.
Add Pfizer to the list of the companies facing a governmental investigation about its ties to copay assistance charities.
U.S. attorneys are asking Regeneron about its relationships with patient assistance nonprofits.
The FDA has savaged U.K.-based Porton Biopharma in a warning letter for repeated contamination of batches of Erwinaze.
Jazz Pharmaceuticals' narcolepsy disease awareness campaign recently got a renewed push: The company reaired its TV spot before the U.S. presidential election.
The specialty pharmacy space has been in somewhat of a rut when it comes to M&A--but that won’t last, Moody’s says.
It’s time for drugmakers to stop relying so much on price increases to grow sales. That’s not a politician speaking; it’s influential Goldman Sachs analyst Jami Rubin, who flagged Jazz, Horizon and Concordia as most dependent on price hikes for growth. Least? That would be Lilly, Regeneron and Gilead.
Jazz has been called out for substantial price hikes on its leading product Xyrem. But now, the company’s cash cow could be in trouble.